OPPM
DRNA

Opus Point Partners Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Opus Point Partners Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-108,000
Closed -$579K – 55
2016
Q1 		$579K Buy
108,000
+8,000
+8% +$50.5K 0.45% 43
2015
Q4 		$1.19M Buy
+100,000
New +$1.14M 0.78% 35

Other funds holding DRNA

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Opus Point Partners Management's DRNA Position: Q2 2016 in Review

Opus Point Partners Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2016, closing a stake of 108,000 shares — an estimated $579K sold.

Opus Point Partners Management first reported a position in DRNA in Q4 2015 and held it in 2 quarters. The position peaked at $1.19M in Q4 2015. 53 funds tracked by Wall St. Rank hold DRNA as of Q2 2016.

  • Opus Point Partners Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Opus Point Partners Management sold 108,000 Dicerna Pharmaceuticals, Inc. shares in Q2 2016, an estimated $579K.
  • Opus Point Partners Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Opus Point Partners Management's Dicerna Pharmaceuticals, Inc. position peaked at $1.19M in Q4 2015.
  • 53 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2016.

Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.